Hansa Biopharma announces decision by Swedish New Therapies Council to recommend use of Idefirix[®] (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients
· Recommendation to use Idefirix[®] (imlifidase) as defined in indication approved by the European Medicines Agency (EMA)[1,2] · Decision provides highly-sensitized patients in Sweden with the opportunity to receive Idefirix[®] as desensitization treatment · Commercial launch activities for Idefirix[®] in Europe progressing as planned Lund, Sweden, June 28, 2021. Hansa Biopharma, “Hansa” (Nasdaq Stockholm: HNSA), the pioneer in enzyme technology for rare immunological conditions, today announced that its first-in-class treatment Idefirix[®] (imlifidase) has received